UPDATED: FDA slaps AstraZeneca's MCL-1 cancer drug with a hold after safety issue — 2 years after Amgen axed a troubled rival
There are new questions being posed about a class of cancer drugs in the wake of the second FDA-enforced clinical hold in the field.
Two years after the FDA hit Amgen with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity, AstraZeneca says that regulators hit them with a hold on their rival therapy of the same class.
The pharma giant noted on clinicaltrials.gov that its Phase I/II study for the MCL-1 drug AZD5991 “has been put on hold to allow further evaluation of safety related information.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.